CG Oncology (CGON) EBITDA Margin (2023 - 2026)
CG Oncology (CGON) reported EBITDA Margin of 6130.1% for Q1 2026, up 7503144.0% on a YoY basis from N/an in Q1 2025, and down 192.28% quarter-over-quarter from 2097.33% in Q4 2025.
CG Oncology (CGON) EBITDA Margin (2023 - 2026) Analysis & Trends
CG Oncology has reported EBITDA Margin for 4 years, with the latest figure at 6130.1% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 7503144.0% year-over-year to 6130.1%; the trailing twelve-month figure through Mar 2026 stood at 4238.99% (up 1606328.0% YoY), and the FY2025 full-year result was 4722.13%, up 534512.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 6130.1%, down from 2097.33% in the prior quarter.
- The five-year high for EBITDA Margin was 2097.33% in Q4 2025, with the low at 1935500.0% in Q4 2023.
- Historically, EBITDA Margin has averaged 208244.27% across 4 years, with a median of 8344.08% in 2024.
- Annual changes were most pronounced in 2024 — EBITDA Margin surged 192715592 bps — and 2025, when it tumbled 7691409 bps.
- CG Oncology's EBITDA Margin stood at 1935500.0% in 2023, then surged by 100 bps to 8344.08% in 2024, then surged by 75 bps to 2097.33% in 2025, then plunged by 192 bps to 6130.1% in 2026.
- The last three EBITDA Margin figures came in at 6130.1% (Q1 2026), 2097.33% (Q4 2025), and 3068.97% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn | -6,130.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,130.10% |
| Dec 31, 2025 | -2,097.33% |
| Sep 30, 2025 | -3,068.97% |
| Mar 31, 2025 | -81,161.54% |
| Dec 31, 2024 | -8,344.08% |
| Sep 30, 2024 | -65,802.33% |
| Jun 30, 2024 | -23,290.99% |
| Mar 31, 2024 | -4,247.45% |
| Dec 31, 2023 | -1,935,500.00% |
| Sep 30, 2023 | -156,033.33% |
| Mar 31, 2023 | -5,010.82% |